Skip to main content

Table 4 Patients’ quality of life and health status

From: Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133+ cells in ischemic refractory cardiomyopathy trial (RECARDIO)

Parameter Baseline 6 months 12 months p value
SF-12
 PCS 38.4 ± 4.6 44.0 ± 6.7 44.4 ± 6.0* 0.02
 MCS 49.8 ± 9.9 49.5 ± 13.2 49.2 ± 15.2 0.99
MLHFQ 35.9 ± 12.2 27.1 ± 10.7 33.1 ± 18.6 0.29
  1. Data presented as mean ± standard deviation
  2. SF-12, Short Form-12, PCS Physical Component Summary, MCS Mental Component Summary, MLHFQ Minnesota Living with Heart Failure Questionnaire
  3. *p ≤ 0.05 vs baseline
Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512